Form 4: ADMA Biologics Director Eduardo Rene Salas Reports Stock and Option Awards

Director Eduardo Rene Salas reports the acquisition of restricted stock units and stock options in ADMA Biologics, Inc.

Summary

• Eduardo Rene Salas, a director of ADMA Biologics, Inc., reported the acquisition of 10,889 restricted stock units (RSUs) and 16,279 stock options on February 19, 2025.
• The RSUs vest in two equal installments over one year.
• The stock options vest in 12 equal monthly installments over one year and have an exercise price of $16.07.
• Following the transaction, Salas beneficially owns 10,889 shares of common stock in the form of RSUs and 16,279 stock options.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the sentiment is neutral.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules encourage continued service and contribution to the company's success.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain talent and align their interests with those of the shareholders.

Stakeholder Impact

• The grant of equity compensation can positively impact employee morale and motivation.
• Shareholders may view the alignment of director interests favorably.

Key Dates

Keywords

ADMA Biologics, Form 4, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Equity Compensation